Expert Opinion on Investigational Drugs · 2017 · 621 citations · 17 references
MedicineGeriatric MedicinePharmacologyDementiaNeurodegenerationNeuropharmacologyAlzheimer DiseaseDementia PharmacotherapyDementia TreatmentNeurodegenerative Disease PharmacotherapyNeurodegenerative DiseasesNeurodegenerative DisordersClinicaltrials.gov RegistrationDementia Drug DevelopmentEnhancersExpert Opinion EvidenceGamma Secretase InhibitionPharmacological Treatment Of DementiaPubmed SearchTreatment Of Cognitive Symptoms
Numerous Alzheimer’s disease drugs have been developed with billions invested, yet the pipeline has seen more failures than successes. The study seeks to explain why Alzheimer’s disease drug trials continue to fail. The authors reviewed failed monoclonal antibodies, gamma‑secretase inhibitors, dimebon, neurochemical enhancers, and a tau drug from 2010‑2015 using PubMed and clinicaltrials.gov data to propose reasons for their failures.
There are dozens of drugs in development for AD with billions of dollars invested. Despite the massive investment in AD drugs and a burgeoning pipeline, there have been more setbacks and failures than treatment successes. Areas covered: The classes of drugs that have failed to date include the monoclonal antibodies, the gamma secretase inhibitors, dimebon, neurochemical enhancers, and one tau drug. Data for these compounds were sought through a PubMed search and a clinicaltrials.gov search. Expert opinion: The obvious question to be posed is: Why are they failing? Is the treatment of symptomatic dementia too late? Are the therapeutic targets incorrect? Are the clinical methodologies imprecise, misleading, or inaccurate? This review summarizes the drugs that have failed during 2010-2015 and offers possible theories as to why they have failed.
17
A new rating scale for Alzheimer's disease
Wilma G. Rosen, Richard C. Mohs, Kenneth L. Davis · American Journal of Psychiatry · 1984 · 4.2K citations
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Neurology, Pharmacology +17
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Neurology, Neuroscience +14
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Rachelle S. Doody, Rema Raman, Martin R. Farlow et al. · New England Journal of Medicine · 2013 · 1.2K citations
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
L. J. Thal, E. Gamzu, Ch Davis et al. · New England Journal of Medicine · 1992 · 627 citations · Full text
Medicine, Neuroscience, Pharmacology +17